Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: Chem Res Toxicol. 2015 May 13;28(6):1156–1166. doi: 10.1021/tx500433r

Figure 4. Rosiglitazone and TBT stimulate adipocyte differentiation in BM-MSCs even in the presence of osteogenic signals.

Figure 4

(A) Primary bone marrow cells were isolated from 8–10 week old male C57BL/6 mice, plated, and allowed to adhere for 7 days. The medium was replaced with MSC medium containing insulin (500 ng/ml). “Medium” wells were left untreated. Cultures were treated with Vh (DMSO, 0.1%), rosiglitazone (Rosi), bexarotene (Bex) or TBT (10–100 nM), cultured for 12–14 days and analyzed for lipid accumulation (Nile Red staining). Data are presented as means ± SE (n=4–9). Statistically different from Vh-treated (*p<0.05, **p<0.01, ANOVA, Dunnett’s). (B) Primary bone marrow cultures were established and osteogenesis was initiated as in Figure 2. Cultures were treated Vh, rosiglitazone, bexarotene or TBT (100 nM), cultured for 12 days and analyzed for lipid accumulation. Data are means ± SE (n=3). Statistically different from Vh-treated (** p<0.01, ANOVA, Dunnett’s). (C) Primary bone marrow cultures were established and osteogenesis was initiated as in Figure 2. Cultures were treated with Vh, rosiglitazone, bexarotene or TBT (100 nM) and cultured for 5 days. Perilipin expression was determined in whole cell lysates by immunoblot. Rosiglitazone-treated samples were loaded with 2-fold less protein. Data are representative of 4 independent bone marrow preparations.